Id |
Subject |
Object |
Predicate |
Lexical cue |
T115 |
0-7 |
Sentence |
denotes |
Results |
T11220 |
9-96 |
Sentence |
denotes |
IL-17 production in PBMC from patients with RA, patients with OA and normal individuals |
T116 |
9-96 |
Sentence |
denotes |
IL-17 production in PBMC from patients with RA, patients with OA and normal individuals |
T11221 |
97-294 |
Sentence |
denotes |
PBMC were separated and cultured with PHA (5 μg/ml) from patients with RA, patients with OA, and age-matched normal controls; IL-17 levels were then determined in the culture supernatants (Fig. 1). |
T117 |
97-294 |
Sentence |
denotes |
PBMC were separated and cultured with PHA (5 μg/ml) from patients with RA, patients with OA, and age-matched normal controls; IL-17 levels were then determined in the culture supernatants (Fig. 1). |
T11222 |
295-634 |
Sentence |
denotes |
Although the amounts of basal IL-17 secretion were not different between RA, OA and normal controls (62 ± 31, 43 ± 19 and 43 ± 10 pg/ml, respectively), the IL-17 production stimulated by PHA was significantly higher in RA PBMC than in those from OA and controls (768 ± 295 versus 463 ± 211 pg/ml [P < 0.05] and 241 ± 29 pg/ml [P < 0.001]). |
T118 |
295-634 |
Sentence |
denotes |
Although the amounts of basal IL-17 secretion were not different between RA, OA and normal controls (62 ± 31, 43 ± 19 and 43 ± 10 pg/ml, respectively), the IL-17 production stimulated by PHA was significantly higher in RA PBMC than in those from OA and controls (768 ± 295 versus 463 ± 211 pg/ml [P < 0.05] and 241 ± 29 pg/ml [P < 0.001]). |
T11761 |
636-728 |
Sentence |
denotes |
Increased IL-17 production in PBMC of patients with RA by anti-CD3 and/or anti-CD28, and PHA |
T119 |
636-728 |
Sentence |
denotes |
Increased IL-17 production in PBMC of patients with RA by anti-CD3 and/or anti-CD28, and PHA |
T11762 |
729-1009 |
Sentence |
denotes |
Because IL-17 was already known from earlier reports to be produced mainly by activated T cells, we investigated the effect of different concentrations of anti-CD3 (1, 5 and 10 μg/ml) as a T cell activation, which showed a dose-dependent increase in IL-17 levels (data not shown). |
T120 |
729-1009 |
Sentence |
denotes |
Because IL-17 was already known from earlier reports to be produced mainly by activated T cells, we investigated the effect of different concentrations of anti-CD3 (1, 5 and 10 μg/ml) as a T cell activation, which showed a dose-dependent increase in IL-17 levels (data not shown). |
T11763 |
1010-1094 |
Sentence |
denotes |
On the basis of this, we chose 10 μg/ml as a stimulation concentration for anti-CD3. |
T121 |
1010-1094 |
Sentence |
denotes |
On the basis of this, we chose 10 μg/ml as a stimulation concentration for anti-CD3. |
T11764 |
1095-1299 |
Sentence |
denotes |
As shown in Table 1, anti-CD3 significantly upregulated IL-17 production up to 3.7-fold, and the combination of anti-CD28 and anti-CD3 produced more IL-17 (approximately 1.3-1.5-fold) than anti-CD3 alone. |
T122 |
1095-1299 |
Sentence |
denotes |
As shown in Table 1, anti-CD3 significantly upregulated IL-17 production up to 3.7-fold, and the combination of anti-CD28 and anti-CD3 produced more IL-17 (approximately 1.3-1.5-fold) than anti-CD3 alone. |
T11765 |
1300-1484 |
Sentence |
denotes |
Furthermore, when incubated with T cell mitogens such as PHA, increased IL-17 production was more pronounced than with anti-CD3 and anti-CD28 (588 ± 85 versus 211 ± 1 pg/ml; P < 0.05). |
T123 |
1300-1484 |
Sentence |
denotes |
Furthermore, when incubated with T cell mitogens such as PHA, increased IL-17 production was more pronounced than with anti-CD3 and anti-CD28 (588 ± 85 versus 211 ± 1 pg/ml; P < 0.05). |
T12597 |
1486-1568 |
Sentence |
denotes |
Regulation of IL-17 production in RA PBMC by inflammatory cytokines and chemokines |
T124 |
1486-1568 |
Sentence |
denotes |
Regulation of IL-17 production in RA PBMC by inflammatory cytokines and chemokines |
T12598 |
1569-1769 |
Sentence |
denotes |
Because RA PBMC include several cell types in addition to T cells, some inflammatory cytokines released from macrophages and other lymphocytes might have affected the production of IL-17 from T cells. |
T125 |
1569-1769 |
Sentence |
denotes |
Because RA PBMC include several cell types in addition to T cells, some inflammatory cytokines released from macrophages and other lymphocytes might have affected the production of IL-17 from T cells. |
T12599 |
1770-1926 |
Sentence |
denotes |
To evaluate the effects of inflammatory cytokines released by activated PBMC, we tested the effects of several cytokines and chemokines on IL-17 production. |
T126 |
1770-1926 |
Sentence |
denotes |
To evaluate the effects of inflammatory cytokines released by activated PBMC, we tested the effects of several cytokines and chemokines on IL-17 production. |
T12600 |
1927-2138 |
Sentence |
denotes |
We detected an increase in IL-17 level after stimulation with IL-15 (10 ng/ml), whereas with IL-1β (10 ng/ml), TNF-α (10 ng/ml), IL-18 (10 ng/ml) or TGF-β (10 ng/ml) the levels in IL-17 were unchanged (Fig. 2a). |
T127 |
1927-2138 |
Sentence |
denotes |
We detected an increase in IL-17 level after stimulation with IL-15 (10 ng/ml), whereas with IL-1β (10 ng/ml), TNF-α (10 ng/ml), IL-18 (10 ng/ml) or TGF-β (10 ng/ml) the levels in IL-17 were unchanged (Fig. 2a). |
T12601 |
2139-2417 |
Sentence |
denotes |
When treated with MCP-1 (10 ng/ml) or IL-6 (10 ng/ml), significant upregulations of IL-17 proteins were observed (62 ± 42 and 50 ± 10 versus 31 ± 11 pg/ml, respectively; P < 0.05), whereas none was observed with IL-8 (10 ng/ml), MIP-1α (10 ng/ml) or MIP-1β (10 ng/ml) (Fig. 2b). |
T128 |
2139-2417 |
Sentence |
denotes |
When treated with MCP-1 (10 ng/ml) or IL-6 (10 ng/ml), significant upregulations of IL-17 proteins were observed (62 ± 42 and 50 ± 10 versus 31 ± 11 pg/ml, respectively; P < 0.05), whereas none was observed with IL-8 (10 ng/ml), MIP-1α (10 ng/ml) or MIP-1β (10 ng/ml) (Fig. 2b). |
T13528 |
2419-2508 |
Sentence |
denotes |
Inhibition of IL-17 production by signal transduction inhibitors and anti-rheumatic drugs |
T129 |
2419-2508 |
Sentence |
denotes |
Inhibition of IL-17 production by signal transduction inhibitors and anti-rheumatic drugs |
T13529 |
2509-2642 |
Sentence |
denotes |
Having observed the increased IL-17 production in RA PBMC, it was important to know which signal transduction pathways were involved. |
T130 |
2509-2642 |
Sentence |
denotes |
Having observed the increased IL-17 production in RA PBMC, it was important to know which signal transduction pathways were involved. |
T13530 |
2643-2906 |
Sentence |
denotes |
As illustrated in Fig. 3, an significant decrease in anti-CD3-induced IL-17 production was observed when co-incubated with NF-κB inhibitor, PDTC and dexamethasone in comparison with anti-CD3 alone (38 ± 5 and 54 ± 11 versus 98 ± 19 pg/ml, respectively; P < 0.05). |
T131 |
2643-2906 |
Sentence |
denotes |
As illustrated in Fig. 3, an significant decrease in anti-CD3-induced IL-17 production was observed when co-incubated with NF-κB inhibitor, PDTC and dexamethasone in comparison with anti-CD3 alone (38 ± 5 and 54 ± 11 versus 98 ± 19 pg/ml, respectively; P < 0.05). |
T13531 |
2907-3115 |
Sentence |
denotes |
LY294002 and wortmannin, as an inhibitor of PI3K, also markedly inhibited the anti-CD3-induced IL-17 production in RA PBMC (98 ± 19 versus 38 ± 10 pg/ml [P < 0.005] and 48 ± 4 pg/ml [P < 0.05], respectively). |
T132 |
2907-3115 |
Sentence |
denotes |
LY294002 and wortmannin, as an inhibitor of PI3K, also markedly inhibited the anti-CD3-induced IL-17 production in RA PBMC (98 ± 19 versus 38 ± 10 pg/ml [P < 0.005] and 48 ± 4 pg/ml [P < 0.05], respectively). |
T13532 |
3116-3358 |
Sentence |
denotes |
The calcineurin inhibitors cyclosporin A and FK506 also downregulated the IL-17 secretion as well as the mitogen-activated protein kinase (MAPK) p38 inhibitor SB203580 did, whereas rapamycin and PD98059 had no effect on IL-17 levels (Fig. 3). |
T133 |
3116-3358 |
Sentence |
denotes |
The calcineurin inhibitors cyclosporin A and FK506 also downregulated the IL-17 secretion as well as the mitogen-activated protein kinase (MAPK) p38 inhibitor SB203580 did, whereas rapamycin and PD98059 had no effect on IL-17 levels (Fig. 3). |
T13533 |
3359-3548 |
Sentence |
denotes |
To evaluate the possibility of non-specific inhibition by the drug at high concentrations, we observed the dose response of PDTC and LY294002 for the inhibition of IL-17 production in PBMC. |
T134 |
3359-3548 |
Sentence |
denotes |
To evaluate the possibility of non-specific inhibition by the drug at high concentrations, we observed the dose response of PDTC and LY294002 for the inhibition of IL-17 production in PBMC. |
T13534 |
3549-3642 |
Sentence |
denotes |
There were dose-dependent inhibitions of IL-17 production with chemical inhibitors (Fig. 4a). |
T135 |
3549-3642 |
Sentence |
denotes |
There were dose-dependent inhibitions of IL-17 production with chemical inhibitors (Fig. 4a). |
T13535 |
3643-3735 |
Sentence |
denotes |
The other inhibitors in addition to PDTC and LY294002 showed the same pattern of inhibition. |
T136 |
3643-3735 |
Sentence |
denotes |
The other inhibitors in addition to PDTC and LY294002 showed the same pattern of inhibition. |
T13536 |
3736-3848 |
Sentence |
denotes |
Cytotoxic effects on PBMC by the chemical inhibitors at experimental concentrations were not observed (Fig. 4b). |
T137 |
3736-3848 |
Sentence |
denotes |
Cytotoxic effects on PBMC by the chemical inhibitors at experimental concentrations were not observed (Fig. 4b). |
T14487 |
3850-3882 |
Sentence |
denotes |
IL-17 mRNA expression in RA PBMC |
T138 |
3850-3882 |
Sentence |
denotes |
IL-17 mRNA expression in RA PBMC |
T14488 |
3883-4051 |
Sentence |
denotes |
To see whether enhanced IL-17 production could be regulated at a transcriptional level, semi-quantatitive reverse transcription–polymerase chain reaction was performed. |
T139 |
3883-4051 |
Sentence |
denotes |
To see whether enhanced IL-17 production could be regulated at a transcriptional level, semi-quantatitive reverse transcription–polymerase chain reaction was performed. |
T14489 |
4052-4240 |
Sentence |
denotes |
We observed a dose-dependent increase in IL-17 mRNA transcripts after stimulation with anti-CD3; this was inhibited by the PI3K inhibitor LY294002 and by the NF-κB inhibitor PDTC (Fig. 5). |
T140 |
4052-4240 |
Sentence |
denotes |
We observed a dose-dependent increase in IL-17 mRNA transcripts after stimulation with anti-CD3; this was inhibited by the PI3K inhibitor LY294002 and by the NF-κB inhibitor PDTC (Fig. 5). |
T14928 |
4242-4324 |
Sentence |
denotes |
Activation of PI3K/Akt signal transduction pathway on IL-17 production by anti-CD3 |
T141 |
4242-4324 |
Sentence |
denotes |
Activation of PI3K/Akt signal transduction pathway on IL-17 production by anti-CD3 |
T14929 |
4325-4444 |
Sentence |
denotes |
To determine downstream effector molecules of the PI3K pathway, we evaluated the activation of Akt by western blotting. |
T142 |
4325-4444 |
Sentence |
denotes |
To determine downstream effector molecules of the PI3K pathway, we evaluated the activation of Akt by western blotting. |
T14930 |
4445-4599 |
Sentence |
denotes |
As shown in Fig. 6, at 10 min of incubation with anti-CD3 (10 μg/ml) or LY294002 (20 μM), no difference in the amounts of phosphorylated Akt was observed. |
T143 |
4445-4599 |
Sentence |
denotes |
As shown in Fig. 6, at 10 min of incubation with anti-CD3 (10 μg/ml) or LY294002 (20 μM), no difference in the amounts of phosphorylated Akt was observed. |
T14931 |
4600-4775 |
Sentence |
denotes |
However, after 30 min of incubation, phosphorylated Akt increased (lane 2), and the effect of inhibition by LY294002 (lane 3) reached a peak at 60 min, lasting to 120–240 min. |
T144 |
4600-4775 |
Sentence |
denotes |
However, after 30 min of incubation, phosphorylated Akt increased (lane 2), and the effect of inhibition by LY294002 (lane 3) reached a peak at 60 min, lasting to 120–240 min. |
T14932 |
4776-4873 |
Sentence |
denotes |
In contrast, non-phosphorylated Akt and β-actin remained unchanged regardless of incubation time. |
T145 |
4776-4873 |
Sentence |
denotes |
In contrast, non-phosphorylated Akt and β-actin remained unchanged regardless of incubation time. |
T14933 |
4874-5071 |
Sentence |
denotes |
PHA, concanavalin A and IL-15 also demonstrated the same effect on phosphorylated Akt as shown with anti-CD3, which was an inhibition by wortmannin and PDTC as well as by LY294002 (data not shown). |
T146 |
4874-5071 |
Sentence |
denotes |
PHA, concanavalin A and IL-15 also demonstrated the same effect on phosphorylated Akt as shown with anti-CD3, which was an inhibition by wortmannin and PDTC as well as by LY294002 (data not shown). |
T15817 |
5073-5164 |
Sentence |
denotes |
Activation of the NF-κB and activator protein-1 (AP-1) pathway in the IL-17 promoter region |
T147 |
5073-5164 |
Sentence |
denotes |
Activation of the NF-κB and activator protein-1 (AP-1) pathway in the IL-17 promoter region |
T15818 |
5165-5453 |
Sentence |
denotes |
To investigate further the intracellular signaling pathway activated by anti-CD3 plus anti-CD28, concanavalin A, PHA and IL-15, and responsible for inducing IL-17 expression, we performed an electrophoretic mobility-shift assay (EMSA) of NF-κB recognition sites in the promoters of IL-17. |
T148 |
5165-5453 |
Sentence |
denotes |
To investigate further the intracellular signaling pathway activated by anti-CD3 plus anti-CD28, concanavalin A, PHA and IL-15, and responsible for inducing IL-17 expression, we performed an electrophoretic mobility-shift assay (EMSA) of NF-κB recognition sites in the promoters of IL-17. |
T15819 |
5454-5658 |
Sentence |
denotes |
As shown in Fig. 7a, nuclear extracts from RA PBMC stimulated with anti-CD3 plus anti-CD28 (lane 2) demonstrated increased binding of NF-κB to IL-17 promoters in comparison with that of controls (lane 1). |
T149 |
5454-5658 |
Sentence |
denotes |
As shown in Fig. 7a, nuclear extracts from RA PBMC stimulated with anti-CD3 plus anti-CD28 (lane 2) demonstrated increased binding of NF-κB to IL-17 promoters in comparison with that of controls (lane 1). |
T15820 |
5659-5758 |
Sentence |
denotes |
A supershift assay demonstrated shifted bands in p65 and p50 (lanes 3 and 4) not in c-Rel (lane 5). |
T150 |
5659-5758 |
Sentence |
denotes |
A supershift assay demonstrated shifted bands in p65 and p50 (lanes 3 and 4) not in c-Rel (lane 5). |
T15821 |
5759-5915 |
Sentence |
denotes |
In normal PBMC the same pattern was observed, but the degree of NF-κB activation by anti-CD3 plus anti-CD28 was less intense than that in RA PBMC (Fig. 7b). |
T151 |
5759-5915 |
Sentence |
denotes |
In normal PBMC the same pattern was observed, but the degree of NF-κB activation by anti-CD3 plus anti-CD28 was less intense than that in RA PBMC (Fig. 7b). |
T15822 |
5916-6071 |
Sentence |
denotes |
To confirm the link between PI3K activity and NF-κB, we performed EMSA to determine the NF-κB binding activity after treatment with both LY294002 and PDTC. |
T152 |
5916-6071 |
Sentence |
denotes |
To confirm the link between PI3K activity and NF-κB, we performed EMSA to determine the NF-κB binding activity after treatment with both LY294002 and PDTC. |
T15823 |
6072-6149 |
Sentence |
denotes |
Both agents block NF-κB DNA-binding activity in the IL-17 promoter (Fig. 7c). |
T153 |
6072-6149 |
Sentence |
denotes |
Both agents block NF-κB DNA-binding activity in the IL-17 promoter (Fig. 7c). |
T15824 |
6150-6267 |
Sentence |
denotes |
Western blotting for IκB-α showed inhibition of degradation of IκB-α by LY294002 and PDTC at the same time (Fig. 7c). |
T154 |
6150-6267 |
Sentence |
denotes |
Western blotting for IκB-α showed inhibition of degradation of IκB-α by LY294002 and PDTC at the same time (Fig. 7c). |
T15825 |
6268-6507 |
Sentence |
denotes |
In contrast, the AP-1 pathway was not activated by stimulation with anti-CD3 plus anti-CD28 (data not shown), demonstrating that NF-κB is the main intracellular signaling pathway in IL-17 production by activated PBMC from patients with RA. |
T155 |
6268-6507 |
Sentence |
denotes |
In contrast, the AP-1 pathway was not activated by stimulation with anti-CD3 plus anti-CD28 (data not shown), demonstrating that NF-κB is the main intracellular signaling pathway in IL-17 production by activated PBMC from patients with RA. |